Mark G Wise, PhD

Lead Scientist
IHMA

Disclosure(s): No financial relationships to disclose

Mark G. Wise, Ph.D. is currently Lead Scientist at IHMA in Schaumburg, Illinois, USA. Holds MS (1994) and PhD (2000) in microbial ecology from the Univ. of Georgia. Formerly employed by the USDA-ARS and BioMerieux. Current research interests include global antimicrobial resistance surveillance and molecular mechanisms of bacterial antimicrobial resistance.

Poster(s):

(P-1355) Trends in Carbapenemase and Co-carbapenemase Production among Enterobacterales in Latin America: SMART 2018-2022

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1514) Cefepime-taniborbactam Exhibits Limited Cross-resistance with Ceftazidime-avibactam and Ceftolozane-tazobactam against Carbapenem-nonsusceptible Enterobacterales and Multidrug-resistant Pseudomonas aeruginosa from the United States 2018-2022

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1518) Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam and Comparators Against Clinical MDR and DTR non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa Stratified by Patient Age and Hospital Ward: SMART United States 2020-2022

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1519) Susceptibility of Clinical Non-Morganellaceae Enterobacterales Isolates from Bloodstream and Respiratory Tract Infections to Imipenem/Relebactam and Comparators: SMART United States 2020-2022

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1520) Addition of Relebactam Increases Susceptibility to Imipenem Among Imipenem-Intermediate Pseudomonas aeruginosa: Asia/Pacific SMART 2018-2022

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1521) Susceptibility of Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) With and Without Carbapenemases to Cefepime-Taniborbactam and Comparators: GEARS Antimicrobial Surveillance Program, United States, 2018-2022

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT